{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:40:49Z","timestamp":1774957249829,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diffuse large B\u2010cell lymphoma (DLBCL) is an aggressive subtype of non\u2010Hodgkin lymphoma with a high rate of disease relapse despite the achievement of clinical responses to frontline chemoimmunotherapy treatments. Loncastuximab tesirine\u2010lpyl is a novel anti\u2010CD19 antibody conjugated to an alkylating pyrrolobenzodiazepine agent (SG3199), and it has been approved for relapsed\/refractory (r\/r) DLBCL. Baseline moderate to severe hepatic impairment has an unclear impact on the safety of loncastuximab tesirine\u2010lpyl, and there is a lack of clear guidance on dose adjustment from the manufacturer. The authors present two cases of r\/r DLBCL safely treated with full\u2010dose loncastuximab tesirine\u2010lpyl in the setting of severe hepatic dysfunction.<\/jats:p>","DOI":"10.1002\/cncr.34816","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T23:30:01Z","timestamp":1684539001000},"page":"2279-2283","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety of loncastuximab tesirine\u2010lpyl in diffuse large B\u2010cell lymphoma with severe hepatic dysfunction"],"prefix":"10.1002","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9972-4794","authenticated-orcid":false,"given":"Grace T.","family":"Baek","sequence":"first","affiliation":[{"name":"Department of Pharmacy UW Medicine  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan J.","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy UW Medicine  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Medical Oncology University of Washington  Seattle Washington USA"},{"name":"Clinical Research Division Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(16)30565\u20104"},{"key":"e_1_2_7_3_1","unstructured":"Turkey tail mushroom.Natural Medicines. Updated August 16 2022. Accessed March 27 2023.https:\/\/naturalmedicines.therapeuticresearch.com"},{"key":"e_1_2_7_4_1","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221087511"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010018\u201028533\u20104"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(21)00139\u2010X"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014663"},{"key":"e_1_2_7_10_1","unstructured":"Loncastuximab for injection for intravenous use (Zylonta\u00ae). Package insert.ADC Therapeutics America;2021."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1590\/0100\u20103984.2018.0013"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201004\u2010703751"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.039"},{"key":"e_1_2_7_14_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology: B\u2010Cell Lymphomas. Version 2.2023.National Comprehensive Cancer Network."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248\u2010021\u201000660\u20103"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:56:39Z","timestamp":1760259399000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.34816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":14,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1002\/cncr.34816"],"URL":"https:\/\/doi.org\/10.1002\/cncr.34816","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"assertion":[{"value":"2023-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}